Guidelines Provided for Diagnosis of Pediatric, Late-Onset Multiple Sclerosis
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 24, 2024 -- In a clinical review conducted by an international committee of multiple sclerosis (MS) experts in pediatric and adult MS and published online Sept. 16 in JAMA Neurology, consensus guidance is provided for diagnosing pediatric and late-onset MS.
Le H. Hua, M.D., from the Lou Ruvo Center for Brain Health at the Cleveland Clinic in Las Vegas, and colleagues provide guidance on approaches to differential diagnosis in suspected MS specific to those aged younger than 18 years and older than 50 years.
The authors note that compared with typical adult-onset MS, unique biological factors are seen in children younger than 18 years and adults older than 50 years. These biological differences may influence clinical presentation, resilience to neuronal injury, and differential diagnosis. Children have high immunological reactivity, increasing the likelihood of other mimicking disorders; consequently, MS needs to be differentiated from other neuroimmunological conditions. The clinical disease course of MS is distinct in children; progressive onset at presentation should warrant investigation for alternative diagnoses. Children are likely to reach disability milestones at earlier ages than adults, underscoring the need for early diagnosis to allow for timely intervention. In older adults, MS should be differentiated from more common conditions such as vascular disease, spinal stenosis/compressive myelopathy, and arthritis. Since inflammatory activity is reduced during older age, relapses triggered by inflammation occur less often, but disability progression tends to accelerate. Nonspecific white matter changes in the brain in older populations are more likely due to vascular disease or migraines, potentially leading to misdiagnosis of MS.
"There are important implications for when MS treatment begins, and improving diagnostic approach is an important step forward in providing tailored care as our research into these patient subsets continues," Hua said in a statement.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-25 12:00
Read more
- FDA Approves Generic GLP-1 Medicine, Liraglutide, (a Victoza Generic), For Diabetes Treatment
- Chatbot "Brains" May Slow with Age
- Metformin Beneficial in Lung Cancer Patients With Overweight, Obesity
- Salmonella Outbreak Triggers Recall of Cucumbers in 26 States
- FDA Approves Steqeyma (ustekinumab-stba), a Biosimilar to Stelara
- Extensive Coronary Artery Calcium on Chest CT Prognostic for Death, CVD
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions